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Objective: To evaluate disease symptoms, and clinical and magnetic resonance imaging (MRI) findings and to perform
longitudinal volumetric MRI analyses in a European multicenter cohort of pediatric anti–N-methyl-D-aspartate receptor
encephalitis (NMDARE) patients.
Methods: We studied 38 children with NMDARE (median age = 12.9 years, range =1–18) and a total of 82 MRI scans
for volumetric MRI analyses compared to matched healthy controls. Mixed-effect models and brain volume z scores
were applied to estimate longitudinal brain volume development. Ordinal logistic regression and ordinal mixed models
were used to predict disease outcome and severity.
Results: Initial MRI scans showed abnormal findings in 15 of 38 (39.5%) patients, mostly white matter T2/fluid-attenuated
inversion recovery hyperintensities. Volumetric MRI analyses revealed reductions of whole brain and gray matter as well as
hippocampal and basal ganglia volumes in NMDARE children. Longitudinal mixed-effect models and z score transformation
showed failure of age-expected brain growth in patients. Importantly, patients with abnormal MRI findings at onset were
more likely to have poor outcome (Pediatric Cerebral Performance Category score > 1, incidence rate ratio = 3.50, 95%
confidence interval [CI] = 1.31–9.31, p = 0.012) compared to patients with normal MRI. Ordinal logistic regression models
View this article online at wileyonlinelibrary.com. DOI: 10.1002/ana.25754
Received Jul 12, 2019, and in revised form Apr 17, 2020. Accepted for publication Apr 18, 2020.
Address correspondence to Dr Finke, Department of Neurology, Charité–Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. E-mail: carsten.
finke@charite.de
From the 1Department of Neurology, Charité–Universitätsmedizin Berlin, Berlin, Germany; 2Berlin School of Mind and Brain, Humboldt-Universität zu
Berlin, Berlin, Germany; 3Department of Pediatric Neurology, Charité–Universitätsmedizin Berlin, Berlin, Germany; 4Center for Chronically Sick Children,
Charité–Universitätsmedizin Berlin, Berlin, Germany; 5Department of Pediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;
6Neuropediatric Unit, Karolinska University Hospital, Astrid Lindgren Children’s Hospital, Stockholm, Sweden; 7Department of Pediatric Neurology,
University Children’s Hospital Augsburg, Augsburg, Germany; 8Department of Pediatrics, Division of Neuropediatric and Social Pediatrics, Medical
University Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen, Aachen, Germany; 9Division of Pediatric Neurology, Department of Pediatrics,
München Klinik Harlaching, Munich, Germany; 10Division of Pediatric Neurology, Department of Pediatrics, Klinikum Weiden, Weiden, Germany;
11Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria; 12Department of Pediatric Neurology, Olgahospital
Stuttgart, Stuttgart, Germany; 13Department of Pediatric Neurology, Children’s Hospital Datteln, Witten/Herdecke University, Datteln, Germany;
14Department of Pediatric Neurology, Children’s Hospital Neuburg, Neuburg, Germany; 15Department of Pediatrics, Marienhospital Bottrop, Bottrop,
Germany; 16Department of Pediatrics, Gottfried von Preyer’s Children’s Hospital, Vienna, Austria; and 17Division of Pediatric Neurology, Department of
Pediatrics, Medical University Münster, Münster, Germany
Additional supporting information can be found in the online version of this article.
© 2020 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.148
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution
and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
corrected for time from onset confirmed abnormal MRI at onset (odds ratio [OR] = 9.90, 95% CI = 2.51–17.28, p = 0.009), a
presentation with sensorimotor deficits (OR = 13.71, 95% CI = 2.68–24.73, p = 0.015), and a treatment delay > 4 weeks
(OR = 5.15, 95% CI = 0.47–9.82, p = 0.031) as independent predictors of poor clinical outcome.
Interpretation: Children with NMDARE exhibit significant brain volume loss and failure of age-expected brain growth.
Abnormal MRI findings, a clinical presentation with sensorimotor deficits, and a treatment delay > 4 weeks are associ-




Anti–N-methyl-D-aspartate receptor encephalitis (NMDARE)
is a well-characterized autoimmune encephalitis associated
with IgG autoantibodies targeting the NR1 subunit of the
NMDA glutamate receptor.1 Symptoms include seizures,
psychosis, memory loss, movement disorders, autonomic
dysfunction, and decreased levels of consciousness.
NMDARE represents one of the most common types of
encephalitis,2,3 and about 40% of all patients are children.4
Similar to adult cases, routine magnetic resonance imaging
(MRI) scans in pediatric NMDARE patients are often
unremarkable, with unspecific MRI changes in about one-
third of patients. These include transient T2 or fluid-
attenuated inversion recovery (FLAIR) hyperintensities,
contrast-enhancing abnormalities, or mild atrophy.5–7 In
adult patients, advanced neuroimaging studies revealed con-
sistent structural and functional MRI changes, including
hippocampal atrophy, white matter damage, and functional
connectivity changes.8–11 In contrast, there has been no sys-
tematic investigation of cerebral MRI changes in pediatric
NMDARE so far. Here, we aimed to (1) evaluate structural
MRI changes in a European cohort of 38 children with
NMDARE and (2) identify potential imaging biomarkers
for disease course and outcome. We longitudinally assessed
MRI changes, performed volumetric MRI analysis with
age-optimized patient matching to a large cohort of healthy
children, and used mixed-effect models and z score transfor-
mation for longitudinal analyses of brain volume changes.
In addition, clinical presentation, diagnostic workup, and
disease course were assessed, and disease severity as well as
clinical outcome were correlated with clinical and MRI vari-
ables using ordinal logistic regression and mixed models.
Subjects and Methods
Patients
Patients were recruited from 13 European hospitals (Charité-Uni-
versitätsmedizin Berlin, Berlin, Germany; University Medical Cen-
ter Hamburg-Eppendorf, Hamburg, Germany; Astrid Lindgren
Children’s Hospital, Karolinska University Hospital, Stockholm,
Sweden; University Children’s Hospital Augsburg, Augsburg,
Germany; Medical University of Vienna, Vienna, Austria; Medical
University of Innsbruck, Innsbruck, Austria; Dr von Hauner’s
Children’s Hospital, Ludwig Maximilian University of Munich,
Munich, Germany; Olgahospital, Stuttgart, Germany; Witten/
Herdecke University, Datteln, Germany; Children’s Hospital
Neuburg, Neuburg, Germany; Marienhospital Bottrop, Bottrop,
Germany; Gottfried von Preyer’s Children’s Hospital, Vienna,
Austria; and Medical University Münster, Münster, Germany). All
caregivers gave written informed consent. The study was approved
by local ethics committees.
FIGURE 1: Patient symptoms. Patient symptoms at first presentation and over the disease course are given as number of
patients (number written at the top or within the bar) and in percent (left y-axis). Incidence rate per 100 patient-months (right
y-axis) is shown with error bars indicating the 95% confidence interval (CI). [Color figure can be viewed at www.
annalsofneurology.org]
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A total of 38 children with NMDARE were included (median
age at disease onset = 12.9 years, range = 1–18, 31 [81.6%] female).
Anti-NMDAR antibodies were confirmed in all patients in serum
and/or cerebrospinal fluid (CSF) by commercially available assays.
Clinical features and disease courses were retrospectively obtained
from patient charts, and parameters such as age at onset, sex, pre-
senting signs and symptoms, prior medical history, NMDAR anti-
body titer, CSF, electroencephalogram, routine MRI findings,
treatment, clinical course, and outcome were collected for all patients
and are presented in Table S1 and Figure 1. Median time for clinical
follow-up was 35 months (range = 12–87 months). Disease severity
and clinical outcome were assessed using the Pediatric Cerebral Per-
formance Category (PCPC) scale.12
Healthy Controls
MRI data from healthy children provided by the NIH MRI
Study of Normal Brain Development were obtained via the Pedi-
atric MRI Data Repository.13 Briefly, this multicenter study
includes serial MRI scans from >500 children, ranging from
infants to young adults. For our analysis, we included a total of
1285 T1-weighted (T1w) MRI scans from 521 healthy children.
Routine MRI Analysis
A total of 102 routine MRI scans (median scans per patient = 2,
range = 1–6) of 38 patients were systematically reviewed to iden-
tify MRI abnormalities. Examples include T2/FLAIR hyper-
intensities, gray/white matter lesions, meningeal enhancement,
and global/regional brain volume loss.
Volumetric MRI Analysis
A total of 82 T1w MRI scans from 35 patients (median time to
first MRI scan = 6 days, range = 0–585 days) were included for
brain volume analysis. To allow reliable automated volumetric
analysis, exclusion criteria for available MRI scans included per-
sistent MRI lesions after herpes simplex virus (HSV) encephalitis
(n = 3 patients, 10 MRI scans), extensive lesions associated with
NMDARE (6 scans), and poor image quality (4 scans), for exam-
ple movement artifacts. Volumetric analysis was performed using
Functional Magnetic Resonance Imaging of the Brain Software
Library (FSL) SIENAX and FSL FIRST. FSL SIENAX uses
tissue-type segmentation estimating normalized whole brain, gray
matter, white matter, cortical gray matter, and ventricular CSF
volumes.14,15 Volumes of subcortical structures were analyzed
with FSL FIRST and normalized to head size using the v-scaling
factor computed by SIENAX.16
Group Comparison
Patient’s brain volumes were first compared to age- and sex-
matched healthy controls (1:10) in a cross-sectional group com-
parison using the MatchIt package for R,17 that is, brain volumes
obtained from 82 patient MRI scans were compared to brain
volumes of 820 matched control MRI scans (patients vs controls,
mean age in years ± standard deviation [SD]: 11.44 ± 5.95 vs
10.55 ± 5.87, p = 0.193; female patients: 71/82 [86.6%] vs
659/820 [80.4%], p = 0.187).
Longitudinal Mixed-Effect Model (Brain Volume)
To account for individual differences in brain development in
the pediatric population and the repeated-measure design, we
applied longitudinal mixed-effect models to estimate individual
longitudinal brain volume trajectories. Mixed-effect models in
pediatric brain volume analysis account for intraindividual corre-
lations and a heterogeneous number of measurements per subject
in longitudinal observations.18 The model was created using the
nlme package for R.19 Fixed effects included group (patients vs
controls), age, time (time from disease onset or first MRI [for
controls]), and sex as well as polynomial order age effects. Ran-
dom effects included random intercepts accounting for varying
interindividual baseline brain volumes and random slopes with
brain volume development varying between subjects over time.
Parameters were added using a forward selection mode, that is,
starting with a simpler model and gradually including more
parameters. The Akaike information criterion (AIC) was applied
to compare the resulting models against each other and select the
one with the best relative model quality. In general, lower AIC
values represent better model quality in terms of goodness of fit
while also penalizing model complexity due to the number of
parameters.20 As such, we selected the model with the lowest
AIC value, which in turn resulted in choosing the simplest
model with no further significant improvement in the log-
likelihood ratio. Sample size correction was not warranted due to
a favorable sample-to-parameter ratio. Including age in the model
variables resulted in significant model improvement when con-
sidered as polynomial effects up to the third order (age3) but not
beyond, such that higher-order polynomial age effects were
discarded.
Z Score Transformation
To additionally estimate patient brain volume changes from
onset over the disease course, z scores were calculated for each
patient MRI scan. This allowed for detection of brain volume
differences of a patient MRI scan compared to its individually
matched healthy control group of the same sex and age range.
Z score transformation of the patient brain volume was calcu-
lated with the following formula: Z = v−μσ , where Z is the patient
brain volume z score, v is the measured patient brain volume,
and μ and σ correspond to the mean and SD of the individual
normative control group. Age- and sex-matched controls were
selected using the MatchIt package for R.17,21 Our aim was to
apply as many controls as possible while permitting biologically
plausible comparability of a patient’s brain volume to its
expected healthy control group. To obtain the best-fitting age
range of the respective control group for each patient MRI, we
applied a data-driven age-matching optimization procedure,
which specifies a maximum permitted age deviation of the mat-
ched controls from the patient age at MRI acquisition. The tra-
deoff between increasing the number of matched controls and
restricting the maximum deviation from the patient age is linked
to the finding that the age distribution in the NIH cohort is not
uniform. As such, more control data are available for some ages
(eg, 10 years old) than for others (eg, 4 years old). We therefore
applied a minimum number (n = 5) of control scans and
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determined the maximum number of matches by quality classifi-
cation, where further matches were added until a specific quality
cutoff was met. Matching quality was categorized into cutoffs at
<2%, <5%, <10%, or <15% age deviation in days, depending on
available data. Strict gender-matching was enforced for all patient
MRIs. This approach allowed for age-adjusted matching with a
stricter age-matching range in younger and a more liberal range
in older children, reflecting the more dynamic brain develop-
ment in younger compared to older children. Overall, matching
quality based on this approach was very good, with the vast
majority of control scans (>80%) adhering to <2% age deviation
from patient age. For each patient MRI scan, the median num-
ber of matches was 16.5 (range = 5–25) and the median percent-
age age deviation in days was 0.64% (range = 0.17%–11.93%).
Incidence Rate (Ratios)
Incidence rates with 95% confidence intervals (CIs) were calcu-
lated for symptoms, PCPC scores, and MRI changes occurring
over the disease course accounting for variable follow-up time.
Incidence rate ratios (IRRs) were calculated comparing incidence
rates for PCPC scores between groups (eg, patients with normal
vs abnormal initial MRI).
Ordinal Logistic Regression and Ordinal Logistic
Mixed-Effects Models (Clinical)
Ordinal logistic regression models were used to predict clinical
outcome (PCPC score at follow-up) and disease severity (maxi-
mum PCPC score). This approach allows for prediction of an
ordinal scale (such as the PCPC scale) from continuous and/or
categorical variables. All models were corrected for time from
onset accounting for variable follow-up. Age at onset and gender
were included (forced entry) to control for these factors.
An additional ordinal logistic mixed-effects model was
built to predict PCPC score using all clinical follow-up data
from a total of 272 patient visits. Models were built using the
clmm function as part of the ordinal package for R. Predictors
included time (logarithmic), age at onset, gender, MRI at
onset, and brain volume z score as fixed effects, and subjects
as random effects. Model building and selection were per-
formed as described above for the brain volume longitudinal
mixed-effect model (see above).
Statistical Analysis
The Shapiro–Wilk test revealed non-normal distribution of all
brain volume parameters. Therefore, volumetric group
FIGURE 2: Clinical routine MRI scans in pediatric anti–N-methyl-D-aspartate receptor encephalitis (NMDARE). Examples are
shown of abnormal findings in routine MRI scans of pediatric NMDARE patients. (A) Small punctuate white matter lesion in the
left frontal lobe on fluid-attenuated inversion recovery (FLAIR) image. (B) Right frontal FLAIR lesion. (C) Bilateral white matter
FLAIR signal alterations around the posterior horns of the lateral ventricles. (D) Cortical signal alteration of the left parietal lobe
in FLAIR sequence. (E) Bilateral FLAIR hyperintensities in the medial temporal lobes, including both hippocampal formations.
(F) Marked global atrophy in T1 sequence (cf Fig 3A for brain volume change over time).
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differences were analyzed using the nonparametric Wilcoxon
rank sum test (equivalent to Mann–Whitney test). Group differ-
ences in categorical data were analyzed using Pearson chi-square
test or Fisher exact test, as appropriate. A point-biserial correla-
tion was run to determine relationships between binary and con-
tinuous variables. Spearman coefficients were calculated for
correlation analyses between 2 continuous variables. All statistical
tests were 2-sided, and p values < 0.05 were considered signifi-
cant. Multiple comparison correction was eschewed due to the
explorative study design and to formulate new hypotheses and
identify new prognostic factors. Analyses were implemented with
custom-written code in R (v3.4.2 for Windows).
FIGURE 3: Brain volume loss and failure of age-expected brain growth in pediatric anti–N-methyl-D-aspartate receptor
encephalitis (NMDARE) patients. (A) Group comparisons between patients and age- and sex-matched healthy controls (1:10) for
whole brain, gray matter, white matter, ventricular, and subcortical volumes (box plots). Asterisks mark significant differences
(p < 0.05). (B) Normalized whole brain volume of NMDARE patients and healthy controls by age (in years). Each point represents
1 magnetic resonance imaging (MRI) scan; the 2 lines represent local polynomial regression fitting (locally estimated scatterplot
smoothing) means with 95% confidence intervals for patients and controls. (C) Longitudinal mixed-effect model of whole brain
volume over time. Note the different trajectories, with each line (representing 1 individual patient) connecting single points
(representing single MRI scans) over time. (D, E) Longitudinal mixed-effect model of gray matter (D) and white matter (E) volume
over time. Lines connect sequential MRI scans from 1 individual subject. [Color figure can be viewed at www.
annalsofneurology.org]




Clinical details are shown in Table S1 and Figure 1. More than
half (52.6% [20/38]) of patients fully recovered (PCPC = 1),
whereas 47% showed mild/moderate (PCPC = 2–3: 21%
[8/38]) to severe (PCPC = 4–6: 5.2% [2/38]) symptoms on
follow-up after a median of 35 months (range = 12–87
months; see Table S1).
Morphological MRI Changes
Routine MRI at disease onset showed abnormal findings
in 15 of 38 (39.5%) children with NMDARE. These
findings included small frontal or frontoparietal white
matter T2/FLAIR hyperintense lesions (<3mm), more
extensive white matter T2/FLAIR hyperintensities, cortical
lesions, and hippocampal and thalamic signal alterations as
well as focal (eg, hippocampal) and/or global atrophy
(Fig 2). MRI changes at any time point during the disease
course were found in 20 of 38 (52.6%) children with an
incidence rate of 1.6 (95% CI = 1.0–2.5) per 100 patient
months, including T2/FLAIR hyperintensities in
brainstem, cerebellum, and frontal, parietal, and occipital
lobes as well as infra- and supratentorial atrophy (see
Fig 2F, Table S1). Three patients showed large temporal
T2/FLAIR lesions characteristic of HSV encephalitis and
were excluded from further volumetric MRI analysis.
Volumetric MRI Analysis
Volumetric MRI analysis revealed whole brain atrophy at all
ages (Fig 3B). A group comparison between patients and age-
and sex-matched healthy controls (1:10) showed significantly
reduced volumes of whole brain and gray matter in patients,
whereas white matter volume was not significantly different
between groups (Table and Fig 3A). Correspondingly, ven-
tricular volume was significantly larger in patients compared
to controls. Subcortical volumetric analysis showed signifi-
cantly reduced volumes of the hippocampus, thalamus, puta-
men, caudate nucleus, and brainstem, but not amygdala and
pallidum in patients.
Figure 3C illustrates the fitted longitudinal whole
brain volume trajectories for individual patients and con-
trols, showing a persistently reduced and declining brain
volume in patients over the disease course. The optimal
longitudinal mixed-effect model included third-order age,
group (patients vs controls), and group*time interaction
as fixed effects, subjects as a random intercept, and age in
subjects as random slope. Importantly, group (patients =
1 and controls = 0; estimated effect = −62.1, 95% CI =
−96.5 to −27.8, p = 4 × 10−4) and the interaction of
group and time (estimated effect = −20.1, 95% CI =
−33.3 to −6.9, p = 0.003) were significant predictors,
indicating not only a significant group difference in brain
volume, but also a failure of normal brain development
over time (negative estimated effect indicating smaller
TABLE. 1. Volumetric Magnetic Resonance Imaging Analysis Group Comparison
Area
Median Volumes, cm3 (IQR)
Wa pPatients Controls
Whole brain 1,634.4 (122.1) 1,756.6 (136.4) 54,197 2.2e-16
Gray matter 833.5 (129.5) 994.1 (120.4) 54,881 2.2e-16
White matter 779.1 (133.9) 758.0 (68.8) 30,964 0.238
Ventricular CSF 27.2 (15.7) 24.3 (9.6) 25,648 3.9e-4
Subcortical
Thalamus 21.4 (3.2) 23.9 (2.3) 36,880 5.1e-14
Putamen 13.3 (3.0) 14.9 (1.9) 32,601 4.1e-07
Caudate nucleus 9.6 (1.3) 10.7 (1.7) 33,816 8.2e-09
Pallidum 4.8 (1.3) 5.0 (0.5) 26,938 0.071
Hippocampus 9.7 (2.3) 10.3 (1.3) 28,752 0.004
Amygdala 3.2 (1.2) 3.4 0.7) 26,476 0.124
Brainstem 24.5 (7.4) 27.3 (4.2) 29,098 0.002
aWilcoxon rank sum test (equivalent to Mann–Whitney test).
IQR = Interquartile range. CSF = Cerebrospinal fluid.
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brain volume in patients vs controls) in patients com-
pared to controls. Similarly, gray matter volume models
suggest reduced volumes (estimated effect = −82.3, 95%
CI = −114.5 to −50.0, p < 0.001) and failure of age-
expected gray matter development over time (estimated
effect = −13.4, 95% CI = −25.8 to −1.0, p = 0.04) in
patients compared to controls, whereas white matter vol-
ume did not differ between patients and controls (esti-
mated effect = 17.1, 95% CI = −10.0 to 44.3, p = 0.22
and estimated effect = −6.2, 95% CI = −16.5 to 4.2,
p = 0.25; see Fig 3D, E).
Z score transformation of each patient MRI allowed
brain volume analysis with respect to disease onset for each
individual patient (Fig 4). This analysis confirmed that patient
brain volumes were generally smaller than the age-expected
brain volume (z score = 0). Graymatter volume showed a simi-
lar volume reduction over 2 years, whereas patients’white mat-
ter showed no relevant volume change over the disease course.
Brain Volume Loss Correlates with Clinical
Outcome
Whole brain and hippocampal volume loss significantly
correlated with follow-up PCPC scores (whole brain:
rho = −0.450, Spearman’s S = 8673.3, p = 0.009; hip-
pocampus: rho = −0.421, p = 0.015). Accordingly,
brain volume z scores of patients with persistent deficits
were significantly smaller compared to patients with full
recovery (median = −2.00, interquartile range [IQR] =
2.21 vs median -1.05, IQR = 1.19, Wilcoxon’s
W = 199, p = 0.016; Fig 5A). Similarly, hippocampus
FIGURE 4: Case vignettes of 2 patients. (A) Progressive brain volume loss in a 2-year-old girl correlating with persistent deficits.
After disease onset with prodromal fever and seizures, the girl developed reduced level of consciousness, sleep problems,
dyskinesia, seizures, and agitation. Treatment included steroids, intravenous immunoglobulin (IVIG), plasma exchange, rituximab,
and cyclophosphamide. At 2-year follow-up, severe intellectual and physical disability remained. Serum antibody titer at onset
was 1:8,000, at 1 month was 1:100, at 2 months was 1:100, at 3 months was 1:320, at 1 year was 1:500, and at 2 years was
negative. (B) Reversible brain volume loss correlating with full recovery in an 11-year-old girl. The patient presented initially with
aggressive behavior and then developed reduced levels of consciousness, hallucinations, aphasia, seizures, and abnormal hand
movements. She was treated with IVIG. At 2-year follow-up, she had a full recovery and was back at school. Serum antibody titer
at onset was 1:100, at 1 month was 1:10, and at 3 months was negative. [Color figure can be viewed at www.
annalsofneurology.org]
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z scores were smaller in patients with persistent deficits
compared to patients with full recovery (median =
−2.34, IQR = 2.55 vs median -0.30, IQR = 1.62,
W = 198, p = 0.017). We did not find any correlations
between different types of treatment and brain volume
loss over time.
Clinical and MRI Predictors of Disease Outcome
Abnormalities on the initial routine MRI scan significantly
correlated with clinical outcome, that is, PCPC score at
follow-up (median = 2, IQR = 1.0 vs median = 1,
IQR = 0.5, W = 80.5, p = 0.003; Pearson’s point biserial
correlation rpb = 0.430, p = 0.007; Fig 5B). Accordingly,
patients with an abnormal initial routine MRI were signifi-
cantly more likely to have persistent deficits (PCPC > 1 vs
PCPC = 0: 80.0% [12/15] vs 26.1% [6/23], IRR = 3.5, 95%
CI = 1.31–9.31, p = 0.012). Abnormal MRI findings at any
time across disease duration correlated even more strongly with
clinical outcome (median = 2, IQR = 1.25 vs median = 1, IQR
= 0, W = 69.5, p = 0.001; rpb = 0.513, p = 0.001; see Fig 5B);
a persistent deficit was found in only 3 patients with a normal
routine MRI (eg, mild deficits in coordination and behavior)
compared to 15 patients with abnormal MRI findings (16.7%
[3/18] vs 75% [15/20], IRR = 5.4, 95% CI = 1.56–18.64,
FIGURE 5: Clinical routine magnetic resonance imaging (MRI) changes and brain volume loss predict disease severity and clinical
outcome. (A, B) Clinical outcome. (A) Patients with a persistent deficit (Pediatric Cerebral Performance Category [PCPC] > 1)
display more brain (left) and hippocampus (right) volume loss (smaller whole brain volume and hippocampus volume z score at
follow-up) compared to patients with full recovery. (B) Patients with an abnormal initial routine MRI (B, upper panel) or an
abnormal MRI at any time (B, lower panel) exhibited poorer clinical outcome. Plot shows median and 10th to 90th quantile.
Asterisks mark significant differences. (C, D) Disease severity. (C) Patients with an abnormal routine MRI at any time during
disease course (C, upper panel), and MRI abnormalities in the hippocampus (C, lower panel) exhibit increased disease severity
(maximum PCPC score). (D) Initial whole brain volume z score correlates with disease severity (maximum PCPC score); Spearman
rho is shown (rho); line represents linear regression with 95% confidence interval. Asterisks mark significant differences
throughout (p < 0.05). [Color figure can be viewed at www.annalsofneurology.org]
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p = 0.008). In addition, a sensory or motor deficit on initial
neurological examination correlated with poor outcome (ie,
PCPC score on clinical follow-up; rpb = 0.451, p = 0.004);
patients presenting with a sensorimotor deficit were at higher
risk for a persistent deficit (IRR = 3.15, 95% CI = 1.12–8.83,
p = 0.029).
Furthermore, we analyzed whether clinical factors
during the disease course correlated with disease outcome;
in an exploratory analysis, there were significant correla-
tions between sensorimotor deficits (rpb = 0.41, p = 0.011)
during the disease course as well as rituximab treatment
(rpb = 0.38, p = 0.017) with worse clinical outcome. How-
ever, applying IRR to account for observation time did
not show significant correlations with clinical outcome. In
addition, there was no correlation between age, gender, or
antibody titer in serum or CSF with PCPC score at
follow-up.
In an ordinal logistic regression model corrected for
follow-up time, clinical outcome (PCPC score) was predicted
by MRI and clinical variables; an abnormal routine
MRI scan at onset (odds ratio [OR] = 9.90, 95%
CI = 2.51–17.28, p = 0.009), a clinical presentation with a
sensorimotor deficit (OR = 13.71, 95% CI = 2.68–24.73,
p = 0.015), and a treatment delay > 4 weeks (OR = 5.15,
95% CI = 0.47–9.82, p = 0.031) were independent signifi-
cant predictors of a worse clinical outcome. Additional signif-
icant predictors in the model included brain volume z score
(OR = −3.69, 95% CI = −6.65 to −0.72, p = 0.015) and
hippocampus volume z score (OR = −1.58, 95% CI =
−2.74 to −0.41, p = 0.008) at last follow-up. Other factors
in the model included follow-up time, age at onset, gender,
intensive care unit (ICU) admission, and CSF cell count
> 20/μl (all not significant predictors).
An additional ordinal logistic mixed-effects model to
account for the longitudinal data structure with variable
follow-up time confirmed an abnormal initial MRI
(OR = 7.06, 95% CI = 2.96–16.80, p = 0.001) and last
brain volume z score (OR = 0.64, 95% CI = 0.50–0.83,
p = 0.001) as significant predictors of the PCPC score.
Other factors included (not significant) were follow-up
time, age at onset, gender, and treatment delay > 4 weeks.
Clinical and MRI Predictors of Disease Severity
Next, we analyzed whether routine MRI, volumetric MRI,
or clinical parameters could predict disease severity as
reflected by a patient’s maximum PCPC score. Lower whole
brain volumes on the initial MRI scan significantly correlated
with a more severe disease course, that is, higher maximum
PCPC scores (rho = −0.531, S = 9162.3, p = 0.001; see
Fig 5D). In addition, presentation with cerebellar ataxia was
associated with a more severe disease course (higher maxi-
mum PCPC score; rpb = 0.670, p = 0.013). Furthermore,
MRI abnormalities at any time during the disease course cor-
related with higher disease severity (maximum PCPC in
abnormal MRI vs normal MRI, median = 5, IQR = 1.0 vs
median = 3, IQR = 1.75; W = 83, p = 0.003; rpb = 0.511,
p = 0.001), specifically when the hippocampus was affected
(median = 5.0, IQR = 0.5 vs median = 4.0, IQR = 2.0;
rpb = 0.292, p = 0.047; see Fig 5C).
A second ordinal logistic regression model correcting
for time from onset was built to predict disease severity.
Here, a lower brain volume on the initial MRI (z score;
OR = −1.90, 95% CI = −3.11 to −0.69, p = 0.002), a
clinical presentation with cerebellar ataxia (OR = 4.54,
95% CI = 0.19–8.88, p = 0.041), and a hippocampus
alteration on MRI (OR = 3.58, 95% CI = 0.48–6.69,
p = 0.024) were independent predictors of a more severe
disease course (maximum PCPC score). Other factors
included in the model were time from onset, age at onset,
and gender (all not significant predictors).
Discussion
We report the first systematic investigation of routine and
advanced MRI analyses in pediatric NMDARE. MRI
abnormalities were present in about 50% of NMDARE
children. Children with abnormal MRIs exhibited a more
severe disease course and a worse outcome compared to
children with unremarkable MRIs. Longitudinal analyses
revealed that children with NMDARE show significant
brain volume loss over time and failure of age-expected
brain growth that is driven by cortical and subcortical gray
matter loss when compared to healthy controls. Impor-
tantly, abnormal findings (eg, T2/FLAIR hyperintensities)
in the initial MRI scan, a sensorimotor deficit at disease
onset, and a treatment delay > 4 weeks correlated with
poor clinical outcome. Furthermore, smaller brain vol-
umes on the initial MRI correlated with higher disease
severity. These neuroradiological measures and clinical fea-
tures may thus become clinically relevant biomarkers for
disease course and outcome in children with NMDARE.
Routine MRI Abnormalities
Around 40% of all patients with NMDARE are younger
than 18 years. Although disease characteristics in children are
generally similar to adult cases, there are important differ-
ences in clinical presentation, such as a higher prevalence of
movement disorders, cerebellar ataxia, and sensorimotor defi-
cits in children.4 In contrast to these severe neurological
symptoms, more than half of all patients have normal rou-
tine MRI scans throughout their disease course. In our
study, routine MRI scans were abnormal in 40% of
patients on initial MRI and in 50% across the disease
course. Similarly, studies in adults reported normal MRIs
in >50% of patients with abnormalities mainly including
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subtle T2/FLAIR hyperintensities in the hippocampus,
basal ganglia, brainstem, white matter, and cerebellar or
cerebral cortex in frontobasal or insular regions.1,10,22–24
In children, abnormalities on routine MRI were found in
31 to 45% of patients.5–7 Whereas these previous studies
suggested a slightly lower frequency of MRI abnormalities
in children compared to adults,25 our data indicate a simi-
lar prevalence. Abnormal MRI findings identified in our
study included cortical, white matter, hippocampal, and
thalamic T2/FLAIR hyperintensities, as well as regional
(eg, hippocampal) and global atrophy. These results con-
firm and extend previously described changes in case series
of pediatric NMDARE MRI that reported T2/FLAIR
hyperintensities, atrophy, sulcal abnormalities, and corti-
cal, parenchymal, or leptomeningeal enhancement.5–7
Brain Atrophy and Failure of Age-Expected
Brain Growth
Using volumetric analyses and longitudinal mixed-effect
models, we found that NMDARE had a severe impact on
the developing brain of children, resulting in brain volume
loss and failure of age-expected brain growth over time.
This is an important difference to our previous volumetric
MRI analyses in adult patients.8 Further analyses of our
pediatric patients revealed reduced cortical and deep gray
matter volume with reduced volumes of hippocampus,
thalamus, and basal ganglia. This is in line with findings
from adult NMDARE patients that identified atrophy and
impaired functional connectivity of the hippocampus that
correlated with memory impairment.8,9 Interestingly,
recent studies showed that many children similarly suffer
from significant cognitive impairment following
NMDARE, suggesting that the hippocampal volume loss
found in our study might associate with impaired cogni-
tive recovery.26,27 Future studies are therefore warranted
to assess the relationship of MRI changes and persistent
cognitive deficits in pediatric NMDARE.
The majority of NMDARE children had persistently
reduced whole brain volumes over time (see Fig 4A), in
contrast to the majority of adult patients, who do not
exhibit whole brain volume loss after the acute disease
stage.8 However, individual brain volume trajectories in
our study indicated reversible brain volume loss with
return to age-expected brain volume in a few children (see
Fig 4B). This is in line with reversible diffuse brain vol-
ume loss that has been reported in single adult cases with
severe disease courses that all required mechanical ventila-
tion and prolonged hospitalization.28 It should be noted,
however, that these reports relied on visual MRI evalua-
tion and did not apply volumetric MRI analyses. In addi-
tion, most children with NMDARE in our study had
only moderate disease severity and nevertheless showed
relevant brain volume loss and failure of age-expected
brain growth. This might indicate a more harmful impact
of NMDARE on the developing brain of children com-
pared to the adult brain. Interestingly, a recent study in
children with acute disseminated encephalomyelitis
(ADEM)—which is rare in adults, but the most common
cause of immune-mediated encephalitis in children before
NMDARE—found that pediatric ADEM patients showed
brain volume loss and failure of age-expected brain
development,29 similar to our findings in pediatric
NMDARE. However, the long-lasting impact on the
developing brain—especially the impact on functional
outcome—remains unclear. To answer this, further pro-
spective longitudinal studies with cognitive outcome mea-
sures are needed.
Clinical and MRI Predictors of Disease Outcome
and Severity
More than half of all patients in our study fully recovered
without any persistent neurological deficit over a median
clinical follow-up of 3 years. This is in line with previous
studies that found substantial improvement or complete
recovery in up to 75% of pediatric cases.4,5 Patients with
a persistent deficit had more severe brain volume loss
compared to patients with full recovery, suggesting a func-
tionally relevant effect of the observed brain atrophy and
failure of age-expected brain growth.
To improve clinical outcome, it is of major clinical
relevance to identify patients at risk for severe disease
courses and persisting deficits as early as possible. This
allows guiding individual treatment decisions, for example,
escalation to second- and third-line therapies, and counsel-
ing families on expected disease trajectory.30 Using logistic
regression and mixed-effect models, we found that an
abnormal routine MRI as well as sensorimotor deficits at
disease onset correlate with a poor clinical outcome. A
sensorimotor deficit was found in up to 20% at initial pre-
sentation and almost 30% over time in our study. Inter-
estingly, focal sensorimotor deficits are more common in
children than in adult patients.4 Nevertheless, motor cor-
tex dysfunction has also been demonstrated in adult
NMDAR patients using functional connectivity MRI ana-
lyses and transcranial magnetic stimulation.11,31 A recent
study identified a score predicting 1-year functional status
in patients with NMDARE: anti-NMDAR Encephalitis
One-Year Functional Status score.30 The score includes
5 variables: treatment delay > 4 weeks, ICU admission,
lack of clinical improvement within 4 weeks, abnormal
MRI, and CSF white blood cell count > 20 cells/μl. In
our study, we could replicate the finding of a treatment
delay > 4 weeks and an abnormal MRI as predictors of
worse clinical outcome. Importantly, we found that an
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abnormal MRI already at first presentation (vs at any time
during disease) was a significant independent predictor of
worse clinical outcome. ICU admission and CSF white
blood cell count > 20 cells/μl were not significant predic-
tors in our data. This study, therefore, complements previ-
ous reports potentially identifying additional clinical
predictors specifically for pediatric patients.
Although predicting disease outcome is the most rel-
evant clinical variable, predicting severity of a patient’s
clinical course can also be helpful for (1) counseling of
patients and parents on the expected disease trajectory and
severity, (2) the decision process for early treatment and
treatment escalation for more severely affected patients,
and (3) inclusion of these parameters in clinical models
for future prospective studies.
Smaller brain volume on initial MRI correlated with
a more severe disease course. This suggests that the biolog-
ical onset of NMDARE in children might precede the
clinical presentation, resulting in brain volume loss already
present on the initial MRI. Similar observations, that is,
reduced brain volumes already at disease onset, have also
been reported in children with multiple sclerosis.18,32
Limitations of the study include the retrospective study
design, the relatively small sample size, especially in some of
the subgroup analyses, and the lack of neuropsychological
data. As this study aimed at exploring new clinical predictors,
multiple comparison was not applied. Further studies are
needed to replicate the findings from this study in larger and
more diverse cohorts, applying a prospective design with
standardized follow-up intervals and including cognitive mea-
sures accounting more accurately for long-term outcome
associated with MRI volume changes.
In summary, our study is the first to systematically
investigate cerebral MRI changes and volumetric MRI ana-
lyses in pediatric NMDARE. Children with NMDARE show
substantial brain volume loss that is driven by cortical and
subcortical gray matter loss as well as failure of age-expected
brain development. Abnormal MRI findings at onset, a pre-
sentation with a sensorimotor deficit, and a treatment delay
> 4 weeks correlate with poor clinical outcome, and initial
brain volume loss correlates with a more severe disease course.
Clinical routine MRI and brain volume changes thus repre-
sent promising biomarkers in pediatric NMDARE that
should be validated in larger prospective studies.
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